Pharma Market Access Insights - from Mtech Access
We explore news and insights from global healthcare markets, advising how pharma and medtech need to respond and adapt their market access strategy in light of the latest insights from our experts. The podcast features insights from our associates across global healthcare, along with thought leadership from the market access and HEOR experts at Mtech Access - Powered by Petauri.
Episodes
65 episodes
Navigating US payer evidence needs to optimise market access
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for t...
•
Season 7
•
Episode 23
•
57:34
Best practice RWE approaches to support economic modelling for HTA
How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?Here, Mtech Access are joined by ...
•
Season 7
•
Episode 22
•
59:53
NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas
How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?In August, Karen Cooper (Senior Consultant – NHS Ins...
•
Season 7
•
Episode 21
•
1:02:50
De-mystifying the NHS – What you need to know about the NHS as a market for your health technology
Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispe...
•
Season 7
•
Episode 20
•
56:15
NHS primary care panel – the GP Contract and Operational Planning Guidance
What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–...
•
Season 7
•
Episode 19
•
1:02:14
Engage NHS healthcare decision-makers with RWD
Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a w...
•
Season 7
•
Episode 18
•
20:55
Market access and reimbursement in Canada – changes at CADTH
What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Gl...
•
Season 5
•
Episode 17
•
47:43
Rare Disease market access in the MENA and Nordic regions
Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you loo...
•
Season 5
•
Episode 16
•
59:10
How does funding flow in NHSE Regions?
Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?We sit down with guest speaker Richard Smale (Interim Direc...
•
Season 5
•
Episode 15
•
1:00:15
NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)
What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive...
•
Season 5
•
Episode 14
•
1:02:06
De-mystifying health economic model classifications and structures
What is health economic evaluation and which modelling approaches can be used to support market access activities?In this episode, our expert health economists explain the key strengths and limitations of the most common health economic...
•
Season 5
•
Episode 13
•
1:00:28
Evidence strategy for Medical Technologies and Diagnostics
Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have th...
•
Season 5
•
Episode 12
•
53:24
How to set your Pharma or Medtech product up for success in the US market
How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launchin...
•
Season 5
•
Episode 11
•
43:06
What's happening with specialised commissioning in the NHS?
What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?Malcolm Qualie (former Medicin...
•
Season 5
•
Episode 10
•
1:00:08
Integrated care in NHS Wales – what can England learn from its neighbour?
What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England?Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (...
•
Season 5
•
Episode 9
•
56:24
Market access in Italy: Reforms at AIFA
Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, part...
•
Season 5
•
Episode 8
•
43:36
Unmet need in NHS primary care – How can industry best support PCN leaders?
Dr Farzana Hussain (GP Principal, The Project Surgery) and Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) explore the unmet needs of Primary Care Networks (PCNs) and how industry can best support primary care leaders a...
•
Season 5
•
Episode 7
•
1:00:44
Population health management: a community effort across health and life sciences
How can our community support NHS leaders to deliver a data-led, people-centric health service?Dr Mark Davies (Global Chief Health Officer, IBM) joins Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) to explore t...
•
Season 5
•
Episode 6
•
1:04:01
Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access
How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access?In th...
•
Season 5
•
Episode 5
•
39:54
6 areas of UK health policy for Medtech to pay attention to
How is the UK political landscape evolving and what does this mean for Health Technology and Medical Device innovators?Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) speaks to William Lee (Head of Policy a...
•
Season 5
•
Episode 4
•
1:01:49
Market access in the German speaking markets
Here we explore market access challenges in Germany, Austria and Switzerland. Clare Foy (Global Market Access Director – Mtech Access) speaks to Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH) a...
•
Season 5
•
Episode 3
•
57:59
The role of nursing in driving digital change in the NHS
How are nursing professionals supporting the digital evolution in UK healthcare? How can new technologies be leveraged by front-line clinical teams to support improved patient care? And how can Medtech, Digital and Biotech innovators collaborat...
•
Season 4
•
Episode 5
•
54:50
Market access for digital therapies and digital medicines
In this Global Whispers webinar we explore market access for digital therapeutics. Clare Foy (Global Market Access Director – Mtech Access) speaks to Shefali Shah (Global VP, Market Value and Commercial Effectiveness – MindMaze) about the chall...
•
Season 5
•
Episode 2
•
42:18
A global market access journey in cannabinoid pharmaceuticals
What does it take to bring a cannabinoid pharmaceutical to market?We were delighted to welcome Michael Sassano (CEO – SOMAÍ Pharmaceuticals) as the first guest on our new Global Whispers webinar series. Michael shared with us his compan...
•
Season 5
•
Episode 1
•
53:47
Primary Care and ICBs – what is the next step in the integration journey?
How will changes to the structure of primary care impact decision making?How is the relationship between Integrated Care Boards (ICBs) and primary care stakeholders evolving? How will funding flows be impacted?Prof. Phil Richardson ...
•
Season 4
•
Episode 4
•
1:01:17
